Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05634369

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue (TINKS)

Sponsor: National Pediatric Cancer Foundation

Conditions Pediatric Sarcoma, Refractory Pediatric Sarcoma, Relapsed

Interventions GEM/DOX + TGFBi expanded NK cells

Updated 20 times since 2023 Last updated: Jan 26, 2026 Started: Nov 14, 2022 Primary completion: Dec 1, 2026 Completion: Dec 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Pediatric Sarcoma, Refractory and Pediatric Sarcoma, Relapsed and is currently actively recruiting participants. National Pediatric Cancer Foundation leads this study, which shows 20 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 15 earlier versions

Feb 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Jan 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2023 — Feb 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Pediatric Cancer Foundation
Nationwide Children's Hospital

Data source: Nationwide Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Buffalo, United States , Chapel Hill, United States , Charlotte, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Durham, United States , Gainesville, United States , Houston, United States , Jacksonville, United States and 12 more locations